NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced the randomization of the last patient in REPLACE, its Phase 3 registration study of NPSP558, a bioengineered form of human parathyroid hormone. REPLACE was a double-blind, placebo-controlled study evaluating the use of NPSP558 as hormone replacement therapy in adult patients with hypoparathyroidism.

Read the rest of this article and more at: http://doubleinstocks.com/?p=14599